Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Personalis to Present at Upcoming Investor Conferences


Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that Aaron Tachibana, Chief Financial Officer and Clinton Musil, Chief Business Officer, are scheduled to present at the following upcoming investor conferences.

About Personalis, Inc.

Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The company's NeXTtm Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).


These press releases may also interest you

at 10:09
The registered nurses and health care professionals of Steward Health Care's Morton Hospital in Taunton yesterday cast an overwhelming vote (96 percent) in favor of authorizing a one-day strike in an effort to convince Steward to provide improvements...

at 10:05
DataLink Software (DataLink), a leading solution to enhance interoperability, reduce costs, improve quality scores and ensure risk adjustment accuracy, has achieved the National Committee for Quality Assurance (NCQA) certification for the Healthcare...

at 10:05
Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino's innovative On-Demand-Cytokine (ODC) platform. Under the terms of strategic alliance,...

at 10:05
The global neuroscience antibodies and assays market is poised to grow by USD 1.36 billion during 2020-2024, progressing at a CAGR of over 8% during the forecast period. Request free sample pages Read the 151-page report with TOC on "Neuroscience...

at 10:05
OurCrowd, the global crowdfunding venture investing platform and Israel's most active venture investor, will showcase select hightech companies from its portfolio of over 200 startups from Israel and around the globe at this year's AIPAC Policy...

at 10:05
Axcend® today announced it has signed a worldwide Integration and Joint Marketing and Sales Agreement with Microsaic Systems (AIM:MSYS). Under terms of the agreement, Axcend and Microsaic will work closely to integrate...



News published on 19 november 2019 at 16:10 and distributed by: